CardiNor has secured NOK 12 million to commercialize the development of an ELISA test for secretoneurin (SN), a potentially new innovative biomarker for cardiovascular disease.
The company will use the funds for CE marking, initiate US regulatory activities and expanding the range of indications, it states in a press release. In addition to existing investors, CardiNor also attracted healthtech specialist Intuitive Investments Group plc (IIG).
“Secretoneurin has the potential to be a game changer in cardiovascular disease,” says Robert Naylor, CEO of IIG. “We were impressed with the CardiNor team’s expertise and vision and look forward to supporting them as they bring the product though to market.”
CardiNor has been able to demonstrate SN’s potential clinical value in two specific areas – support patient selection for implantable cardioverter defibrillators and heart failure patient discharge eligibility.
“We are delighted to have closed this latest round and attracted international investors of the calibre of IIG,” says Dag Christiansen, CEO, CardiNor. “The rise of heart failure worldwide is alarming and described as reaching pandemic levels. Our aim is to develop a routine test for this important marker which we believe will provide clinicians with a key tool for both more accurate risk prediction and patient management.”